Article cité par

La fonctionnalité Article cité par… liste les citations d'un article. Ces citations proviennent de la base de données des articles de EDP Sciences, ainsi que des bases de données d'autres éditeurs participant au programme strong>CrossRef Cited-by Linking Program. Vous pouvez définir une alerte courriel pour être prévenu de la parution d'un nouvel article citant " cet article (voir sur la page du résumé de l'article le menu à droite).

Article cité :

Citations de cet article :

Doping control analysis of trimetazidine and characterization of major metabolites using mass spectrometric approaches

Gerd Sigmund, Anja Koch, Anne-Katrin Orlovius, et al.
Drug Testing and Analysis 6 (11-12) 1197 (2014)
DOI: 10.1002/dta.1680
Voir cet article

Structure–activity studies on the protection of Trimetazidine derivatives modified with nitroxides and their precursors from myocardial ischemia–reperfusion injury

Tamás Kálai, Mahmood Khan, Mária Balog, et al.
Bioorganic & Medicinal Chemistry 14 (16) 5510 (2006)
DOI: 10.1016/j.bmc.2006.04.040
Voir cet article

The Impact of Trimetazidine on Disease Severity and Quality of Life in Parkinson’s Disease

Dávid Pintér, Annamária Juhász, Márk Harmat, József Janszky and Norbert Kovács
Scientific Reports 10 (1) (2020)
DOI: 10.1038/s41598-020-66692-5
Voir cet article

Cinnarizine- and flunarizine-associated movement disorder: a literature review

Jamir Pitton Rissardo and Ana Letícia Fornari Caprara
The Egyptian Journal of Neurology, Psychiatry and Neurosurgery 56 (1) (2020)
DOI: 10.1186/s41983-020-00197-w
Voir cet article

Drug-induced parkinsonism

Maria A Mena and Justo G de Yébenes
Expert Opinion on Drug Safety 5 (6) 759 (2006)
DOI: 10.1517/14740338.5.6.759
Voir cet article

Trimetazidine-Induced Parkinsonism: A Systematic Review

Anna Marielle B. Dy, Lorenzo Luis G. Limjoco and Roland Dominic G. Jamora
Frontiers in Neurology 11 (2020)
DOI: 10.3389/fneur.2020.00044
Voir cet article

Encéphalopathie avec mouvements choréiformes induits par la trimétazidine : à propos d’un cas

J. Sivet, B. de la Gastine, B. Mosquet, et al.
La Revue de Médecine Interne 29 (6) 512 (2008)
DOI: 10.1016/j.revmed.2007.12.001
Voir cet article

Drug-induced parkinsonism

José López-Sendón, Maria A Mena and Justo G de Yébenes
Expert Opinion on Drug Safety 12 (4) 487 (2013)
DOI: 10.1517/14740338.2013.787065
Voir cet article

The prevalence of trimetazidine use in athletes in Poland: excretion study after oral drug administration

Anna Jarek, Marzena Wójtowicz, Dorota Kwiatkowska, et al.
Drug Testing and Analysis 6 (11-12) 1191 (2014)
DOI: 10.1002/dta.1755
Voir cet article

Antipsychotic-Like Effect of Trimetazidine in a Rodent Model

Oytun Erbaş, Hüseyin Serdar Akseki, Betül Eliküçük and Dilek Taşkıran
The Scientific World Journal 2013 1 (2013)
DOI: 10.1155/2013/686304
Voir cet article

Diagnostic accuracy of 123I-FP-CIT SPECT in diagnosing drug-induced parkinsonism: A prospective study

J. Olivares Romero and A. Arjona Padillo
Neurología (English Edition) 28 (5) 276 (2013)
DOI: 10.1016/j.nrleng.2012.05.007
Voir cet article

Utilidad de la tomografía por emisión de fotón simple con 123Ioflupano en el diagnóstico del parkinsonismo relacionado con fármacos. Estudio prospectivo

J. Olivares Romero and A. Arjona Padillo
Neurología 28 (5) 276 (2013)
DOI: 10.1016/j.nrl.2012.05.005
Voir cet article

Respuesta a Idaptan® (trimetazidina): la panacea

Carmelo Aguirre, Montserrat García García and Ainhoa Etxebarria Aretxaga
Atención Primaria 46 (1) 51 (2014)
DOI: 10.1016/j.aprim.2013.04.011
Voir cet article

Extrapyramidal adverse drug reactions associated with trimetazidine: a series of 21 cases

Kamel Masmoudi, Henri Masson, Valérie Gras and Michel Andréjak
Fundamental & Clinical Pharmacology 26 (2) 198 (2012)
DOI: 10.1111/j.1472-8206.2011.01008.x
Voir cet article

Taking Diabetes to Heart—Deregulation of Myocardial Lipid Metabolism in Diabetic Cardiomyopathy

Marina Bayeva, Konrad Teodor Sawicki and Hossein Ardehali
Journal of the American Heart Association 2 (6) (2013)
DOI: 10.1161/JAHA.113.000433
Voir cet article

Trimetazidine Revisited: A Comprehensive Review of the Pharmacological Effects and Analytical Techniques for the Determination of Trimetazidine

A. Onay-Besikci and S.A. Özkan
Cardiovascular Therapeutics 26 (2) 147 (2008)
DOI: 10.1111/j.1527-3466.2008.00043.x
Voir cet article

Drug-induced parkinsonism in the elderly

Kelvin L Chou and Joseph H Friedman
Future Neurology 2 (3) 307 (2007)
DOI: 10.2217/14796708.2.3.307
Voir cet article

Trimetazidine and parkinsonism: A prospective study

Dávid Pintér, Márton Kovács, Márk Harmat, et al.
Parkinsonism & Related Disorders 62 117 (2019)
DOI: 10.1016/j.parkreldis.2019.01.005
Voir cet article

Defining the Role of Trimetazidine in the Treatment of Cardiovascular Disorders: Some Insights on Its Role in Heart Failure and Peripheral Artery Disease

Piotr Chrusciel, Jacek Rysz and Maciej Banach
Drugs 74 (9) 971 (2014)
DOI: 10.1007/s40265-014-0233-5
Voir cet article

Cardiac metabolism — A promising therapeutic target for heart failure

Hannah Noordali, Brodie L. Loudon, Michael P. Frenneaux and Melanie Madhani
Pharmacology & Therapeutics 182 95 (2018)
DOI: 10.1016/j.pharmthera.2017.08.001
Voir cet article

Trimetazidine Use and the Risk of Parkinsonism: A Nationwide Population-Based Study

Seungyeon Kim, Yun Mi Yu, Jeongyoon Kwon, et al.
International Journal of Environmental Research and Public Health 17 (19) 7256 (2020)
DOI: 10.3390/ijerph17197256
Voir cet article

Trimetazidine in Practice

Csaba A. Dézsi
American Journal of Therapeutics 23 (3) e871 (2016)
DOI: 10.1097/MJT.0000000000000180
Voir cet article

Drug-induced parkinsonism: A review of 17 years' experience in a regional pharmacovigilance center in France

Emmanuelle Bondon-Guitton, Santiago Perez-Lloret, Haleh Bagheri, et al.
Movement Disorders 26 (12) 2226 (2011)
DOI: 10.1002/mds.23828
Voir cet article

La trimétazidine (Vastarel) est-elle un produit dopant ? Proposition pour une suppression de la liste des produits interdits de l’Agence mondiale anti-dopage

Pascal Kintz
Toxicologie Analytique et Clinique 32 (4) 239 (2020)
DOI: 10.1016/j.toxac.2020.09.079
Voir cet article

Evidence of Repurposing Drugs and Identifying Contraindications from Real World Study in Parkinson’s Disease

Yilin Tang, Ke Yang, Jue Zhao, Xiaoniu Liang and Jian Wang
ACS Chemical Neuroscience 10 (2) 954 (2019)
DOI: 10.1021/acschemneuro.8b00456
Voir cet article

Extra energy for hearts with a genetic defect: ENERGY trial

B. O. van Driel, A. C. van Rossum, M. Michels, R. Huurman and J. van der Velden
Netherlands Heart Journal 27 (4) 200 (2019)
DOI: 10.1007/s12471-019-1239-0
Voir cet article

The Inclusion in WADA Prohibited List Is Not Always Supported by Scientific Evidence: A Narrative Review

Eduard Bezuglov, Oleg Talibov, Mikhail Butovskiy, et al.
Asian Journal of Sports Medicine 12 (2) (2021)
DOI: 10.5812/asjsm.110753
Voir cet article